Please login to the form below

Not currently logged in
Email:
Password:

GSK paid $1bn to settle Paxil lawsuits

GlaxoSmithKline (GSK) has paid almost $1bn to resolve lawsuits over its antidrepressant Paxil since it was introduced in 1993

GlaxoSmithKline (GSK) has paid almost $1bn to resolve lawsuits over its antidrepressant Paxil since it was introduced in 1993. Analysts have said the amount is higher than what was expected.

The total paid by the UK's largest pharmaceutical company includes around $390m for cases regarding suicides or attempted suicides reportedly linked to the drug; a further $200m to settle lawsuits of addiction and birth defects; and $400m over antitrust and fraud claims.

However, the $1bn does not include the additional 600+ outstanding claims that Paxil caused birth defects. Only 10 such cases have been settled, at an average cost of $4m to GSK. In one case, settled in October 09, GSK was ordered to pay $2.5m in compensatory damages. Based on these figures, the company may face an additional liability of around $1.5bn.

GSK has declined to confirm the $1bn figure. Spokesperson Sarah Alspach said: "Paxil has been on the market in the US since 1993. Like many other pharmaceutical products, it has been the subject of different kinds of litigation over the years. It would be inappropriate and potentially misleading to aggregate payments in these various types of litigation."

15th December 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics